ACE inhibitor (Enalapril 2.5 - 20mg/day (uptitrated as tolerated) vs placebo, CKD

Polypharmacy icon of two pills

Study population:

Patients with heart failure and Chronic Kidney Disease

(NYHA class I - IV) due to left ventricular systolic dysfunction (ejection fraction ≤0.35).

eGFR <60 mL /min /1.73m2

Comments:

Mean age of patients was 64 years. Approximately 75% were male.

 

Outcome Duration NNT Annualised NNT
Prevent one death (any cause) 34 months (mean followup)

29

101

References

Bowling C.B., Sanders P.W., Allman R.M., Rogers W.J et al. Effects of enalapril in systolic heart failure patients with and without chronic kidney disease: Insights from the SOLVD Treatment trial. International Journal of Cardiology. 2013; 167 (1): 151-156